Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex

Targeting the dysregulated BRaf-MEK-ERK pathway in cancer has increasingly emerged in clinical trial design. Despite clinical responses in specific cancers using inhibitors targeting BRaf and MEK, resistance develops often involving non-genomic adaptive bypass mechanisms. Inhibition of MEK1/2 by tra...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Cancer Discov
Główni autorzy: Zawistowski, Jon S., Bevill, Samantha M., Goulet, Daniel R., Stuhlmiller, Timothy J., Beltran, Adriana S., Olivares-Quintero, Jose F., Singh, Darshan, Sciaky, Noah, Parker, Joel S., Rashid, Naim U., Chen, Xin, Duncan, James S., Whittle, Martin C., Angus, Steven P., Velarde, Sara Hanna, Golitz, Brian T., He, Xiaping, Santos, Charlene, Darr, David B., Gallagher, Kristalyn, Graves, Lee M., Perou, Charles M., Carey, Lisa A., Earp, H. Shelton, Johnson, Gary L.
Format: Artigo
Język:Inglês
Wydane: 2017
Hasła przedmiotowe:
Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5340640/
https://ncbi.nlm.nih.gov/pubmed/28108460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0653
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy